Milestone Pharmaceuticals ( ($MIST) ) has issued an announcement. On January 6, 2026, Milestone Pharmaceuticals announced that the European ...

European decision on approval is expected by Q1 2027If approved, etripamil nasal spray is expected to offer patients a safe and effective ...

Focussing only on heart attacks may be incomplete. Listen to your heartbeat closely to prevent sudden cardiac arrest, says ...

CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Aptar Group, Inc. (NYSE: ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today announced that its Bidose (BDS) ...

The FDA approved etripamil (Cardamyst) nasal spray for at-home treatment of paroxysmal supraventricular tachycardia (PSVT), maker Milestone Pharmaceuticals announced. The rapid-acting L-type calcium ...

CRYSTAL LAKE, Ill. - Aptar Group, Inc. (NYSE:ATR) announced that its Bidose Liquid Nasal Spray System will be used to deliver CARDAMYST (etripamil), a treatment recently approved by the U.S. Food and ...

Aptar Group, Inc. (NYSE: ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today announced that its Bidose (BDS) Liquid Nasal Spray System is the ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved a rapid-acting nasal spray for the treatment of acute symptomatic paroxysmal supraventricular ...

Intranasal etripamil is the first self-administered, on-demand therapy for PSVT, allowing treatment outside healthcare settings. The RAPID trial showed 64% of etripamil-treated patients returned to ...

Milestone Pharmaceuticals Inc. received FDA approval for CARDAMYST, a nasal spray for acute PSVT episodes, but faces a challenging commercialization path. The PSVT market is crowded with effective, ...

Greetings. Welcome to Milestone Pharmaceuticals CARDAMYST FDA Approval Call. [Operator Instructions] Please note, this conference is being recorded. I will now turn the conference over to Michael Wood ...